

# Financial Tear Sheet

## Primary IR Contact

Ed Bell  
T +1 206-272-4345  
invest@ctibiopharma.com  
(mailto:invest@ctibiopharma.com)

## Transfer Agent

### Computershare

Mail:  
Computershare Investor Services  
P.O. Box 43078  
Providence, RI 02940-3078

Overnight Delivery:  
Computershare Investor Services  
250 Royall Street  
Canton, MA 02021  
United States of America

T: 312-588-4187  
F: 312-601-4332  
www.Computershare.com  
(http://www.computershare.com)

## Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

## Stock Performance: CTIC (Nasdaq)

**Exchange** NASDAQ CM (US Dollar)

**Price** **\$3.28**

**Change (%)** ▲ 0.08 (2.50%)

**Volume** 197,287

**52 Week Low** \$2.70

**Market Cap** \$137,543,696

**Rolling EPS** -1.80

**PE Ratio** 0

**Shares Outstanding** 42,982,405

Data as of 09/21/17 4:00 p.m. ET



## Recent Headlines & Events

Aug 31, 2017 - 1:30 a.m.

CTI BioPharma to Present at the  
BioCentury NewsMakers in the Biotech  
Industry Conference  
([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2297579](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2297579))

Aug 03, 2017 - 4:02 p.m.

CTI BioPharma Reports Second Quarter  
2017 Financial Results  
([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2291660](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2291660))

Aug 02, 2017 - 1:30 a.m.

CTI BioPharma Announces Completion of  
Enrollment in the Phase 3 PIX306 Trial of  
PIXUVRI® for Aggressive B-cell  
non-Hodgkin lymphoma  
([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2290871](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2290871))

There are currently no events scheduled.

## Ownership Summary

### Shareholders

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	66	77.26	51.5	22,136,330
Mutual Fund	20	3.23	2.3	977,667
Insider *	11	24.27	11.6	4,969,236

*\*Insider values reflect direct beneficial ownership.*

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
BVF Partners L.P.	8,596,357	20.0	4,116,666	06/30/17
OrbiMed Advisors, LLC	5,000,000	11.6	5,000,000	06/30/17
Stonepine Capital Management, LLC	2,284,381	5.3	2,284,381	06/30/17
Baxalta, Inc.	1,567,398	3.7	0	01/01/17
NB Public Equity Komplementar ApS	1,356,635	3.2	90,000	12/31/16
The Vanguard Group, Inc.	753,379	1.8	-59,119	06/30/17
Alyeska Investment Group, L.P.	466,529	1.1	466,529	06/30/17
BlackRock Institutional Trust Company, N.A.	380,407	0.9	28,348	06/30/17
Susquehanna Financial Group, LLLP	250,636	0.6	250,636	06/30/17
Bianco (James A)	178,013	0.4	-153,379	02/10/17

*Data provided by Nasdaq. Minimum 15 minutes delayed.*